8-K: 10x Genomics Swings to Profit on Settlement Gain

10x Genomics reported a significant turnaround in Q2 2025 financial performance, driven by a patent litigation settlement and improved gross margins, despite a slight decrease in core revenue.

Summary

• Total revenue for Q2 2025 was $172.9 million, which includes $27.3 million from a patent litigation settlement.
• Excluding the settlement, Q2 2025 revenue was $145.6 million, representing a 5% decrease from Q2 2024, primarily due to lower instrument revenue.
• Net income for Q2 2025 was $34.5 million, a significant improvement compared to a net loss of $37.9 million in the corresponding prior year period.
• Operating income for Q2 2025 was $30.1 million, reversing an operating loss of $41.7 million in Q2 2024.
• Gross margin increased to 72% for Q2 2025, up from 68% in Q2 2024, primarily due to higher license and royalty revenue and lower royalties and warranty costs.
• Operating expenses decreased by 35% to $95.0 million in Q2 2025, largely due to a $40.7 million gain on the litigation settlement.
• Cash and cash equivalents and marketable securities stood at $447.3 million as of June 30, 2025, an increase of $20 million from the prior quarter.
• The company entered into a definitive agreement to acquire Scale Biosciences for $30 million in upfront cash and stock, plus potential contingent consideration.
• Visium HD 3 and HD cell segmentation began shipping, expanding the Visium portfolio's capabilities.
• A partnership was announced with the Genome Institute of Singapore for the TISHUMAP initiative, leveraging Xenium and AI for biomarker discovery in cancer and inflammatory diseases.
• Q3 2025 revenue guidance is projected to be in the range of $140 million to $144 million, reflecting approximately $4.0 million of revenue accelerated from Q3 into Q2 by Chinese customers anticipating tariff changes.

Sentiment

Score: 7

Explanation: The company achieved significant profitability and cash growth in Q2 2025, largely due to a one-time litigation settlement. While core revenue declined and future guidance is lower, strategic acquisitions and product launches indicate continued innovation and long-term potential. The underlying business performance shows some weakness, but the overall financial health improved substantially for the quarter.

Positives

• Achieved net income of $34.5 million in Q2 2025, a substantial turnaround from a net loss of $37.9 million in Q2 2024.
• Reported operating income of $30.1 million, reversing an operating loss of $41.7 million in the prior year period.
• Gross margin improved to 72% (67% excluding license/royalty revenue) from 68% in Q2 2024.
• Cash and cash equivalents and marketable securities increased by $20 million to $447.3 million.
• Strategic acquisition of Scale Biosciences is expected to strengthen leadership in single cell analysis and expand access to technology.
• Launched and began shipping Visium HD 3 and HD cell segmentation, enhancing product capabilities.
• Formed a key partnership with the Genome Institute of Singapore to advance research in cancer and inflammatory diseases.
• Benefited from a $40.7 million gain on litigation settlement, significantly reducing operating expenses.

Negatives

• Core revenue (excluding the patent litigation settlement) decreased by 5% to $145.6 million compared to Q2 2024.
• The decrease in core revenue was primarily driven by a decline in instrument revenue.
• Q3 2025 revenue guidance of $140 million to $144 million is lower than Q2 2025 core revenue, indicating a potential slowdown.
• Approximately $4.0 million of Q3 revenue was pulled into Q2 due to anticipated tariff changes in China, which will negatively impact Q3 results.
• Management noted continued uncertainty in the funding environment.

Risks

• Continued uncertainty in the funding environment may impact future business resilience and growth.
• Potential tariff changes could influence customer purchasing behavior and revenue timing, as seen with accelerated purchases from China.

Future Outlook

10x Genomics expects third quarter 2025 revenue to be in the range of $140 million to $144 million, which accounts for approximately $4.0 million of revenue accelerated from Q3 into Q2 due to anticipated tariff changes in China. Management remains confident in the strength of its technology, the momentum behind its platforms, and the significant long-term opportunity, despite continued uncertainty in the funding environment.

Management Comments

• "The second quarter unfolded largely as anticipated." Serge Saxonov, Co-founder and CEO.
• "Amid continued uncertainty in the funding environment, we're encouraged by the resilience of our business and the dedication of our team." Serge Saxonov, Co-founder and CEO.
• "We're focused on disciplined execution, and remain confident in the strength of our technology, the momentum behind our platforms and the significant long-term opportunity in front of us." Serge Saxonov, Co-founder and CEO.

Industry Context

Operating in the dynamic life science technology sector, 10x Genomics specializes in single cell and spatial biology, critical areas for advancing human health. The acquisition of Scale Biosciences and the partnership with the Genome Institute of Singapore highlight the company's strategy to expand its technological leadership and application reach within these high-growth fields. The acknowledgment of 'continued uncertainty in the funding environment' reflects broader macroeconomic pressures impacting research and development investments across the biotechnology and life science tools industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or industry benchmarks to assess the results against global standards. The analysis is focused solely on the company's internal performance and strategic initiatives.

Legal Proceedings

• A patent litigation settlement resulted in $27.3 million in license and royalty revenue and a $40.7 million gain on settlement, contributing to the company's Q2 2025 financial results.

Stakeholder Impact

• Shareholders: Experienced a significant improvement in net income and operating income, though this was largely driven by a one-time settlement. Core revenue decline and lower Q3 guidance may temper enthusiasm.
• Customers: Benefit from expanded product capabilities with the shipping of Visium HD 3 and HD cell segmentation, and the acquisition of Scale Biosciences is expected to enable more powerful, affordable, and scalable experiments.
• Employees: Management emphasized the resilience of the business and dedication of the team amid continued uncertainty in the funding environment, suggesting a focus on disciplined execution.

Next Steps

• Host a conference call on August 7, 2025, to discuss the second quarter 2025 financial results, business developments, and outlook.
• File the quarterly report on Form 10-Q for the quarter ended June 30, 2025, with the Securities and Exchange Commission (SEC).
• Integrate Scale Biosciences following the acquisition to strengthen single cell analysis capabilities.
• Continue disciplined execution and focus on the strength of technology and momentum behind platforms.

Key Dates

Recommendation

While the company reported a strong net income and operating income for the quarter, this was significantly boosted by a one-time patent litigation settlement. The underlying product and services revenue saw a 5% decrease, and the guidance for Q3 2025 is lower than the core Q2 revenue, indicating ongoing challenges in the funding environment and instrument sales. The strategic acquisition and product launches are positive long-term moves, but the immediate core business trends suggest caution. Investors should hold to see if the company can return to organic revenue growth in subsequent quarters without the benefit of one-time gains.

Keywords

Genomics, Single Cell Biology, Spatial Biology, Biotechnology, Life Science Technology, Financial Results, Earnings, Acquisition, Research Tools, Cancer Research, Immunology, Neuroscience